• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[心力衰竭的诊断与治疗进展]

[Update on diagnostics and treatment of heart failure].

作者信息

Wintrich Jan, Berger Ann-Kathrin, Bewarder Yvonne, Emrich Insa, Slawik Jonathan, Böhm Michael

机构信息

Klinik für Innere Medizin III - Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrbergerstraße, 666421, Homburg/Saar, Deutschland.

出版信息

Herz. 2022 Aug;47(4):340-353. doi: 10.1007/s00059-021-05062-x. Epub 2021 Aug 31.

DOI:10.1007/s00059-021-05062-x
PMID:34463784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8405859/
Abstract

The incidence and prevalence of heart failure are increasing worldwide. Despite numerous scientific and clinical innovations the mortality and morbidity rates in heart failure patients remain high, so that guideline-conform diagnostics and treatment are of decisive importance. Cardiac decompensation is one of the leading reasons for hospital admissions in Germany. Thus, the treatment of patients with heart failure represents a substantial challenge for the German healthcare system. This article highlights the latest scientific knowledge on acute and chronic heart failure from the years 2018-2020.

摘要

心力衰竭的发病率和患病率在全球范围内都在上升。尽管有众多科学和临床创新，但心力衰竭患者的死亡率和发病率仍然很高，因此符合指南的诊断和治疗至关重要。心脏失代偿是德国住院治疗的主要原因之一。因此，心力衰竭患者的治疗对德国医疗保健系统构成了重大挑战。本文重点介绍了2018 - 2020年期间关于急性和慢性心力衰竭的最新科学知识。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/1212f24f266c/59_2021_5062_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/87a6fe468371/59_2021_5062_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/e561ef4d5d77/59_2021_5062_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/9d44317048a6/59_2021_5062_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/4c0bc2cb5232/59_2021_5062_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/9f9f71b80b6a/59_2021_5062_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/e05404979104/59_2021_5062_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/0d43312c997b/59_2021_5062_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/1212f24f266c/59_2021_5062_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/87a6fe468371/59_2021_5062_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/e561ef4d5d77/59_2021_5062_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/9d44317048a6/59_2021_5062_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/4c0bc2cb5232/59_2021_5062_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/9f9f71b80b6a/59_2021_5062_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/e05404979104/59_2021_5062_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/0d43312c997b/59_2021_5062_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0dce/9355934/1212f24f266c/59_2021_5062_Fig8_HTML.jpg

相似文献

1
[Update on diagnostics and treatment of heart failure].[心力衰竭的诊断与治疗进展]
Herz. 2022 Aug;47(4):340-353. doi: 10.1007/s00059-021-05062-x. Epub 2021 Aug 31.
2
[Update on heart failure].[心力衰竭的最新进展]
Herz. 2020 Apr;45(2):158-169. doi: 10.1007/s00059-018-4715-1. Epub 2018 Jun 5.
3
[Evidence-based drug therapy for heart failure-an update].
Herz. 2020 Dec;45(Suppl 1):37-45. doi: 10.1007/s00059-019-4827-2. Epub 2019 Jun 24.
4
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.维立西呱治疗射血分数降低的心力衰竭患者的疗效。
N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28.
5
[The German National Disease Management Guideline "Chronic Heart Failure"].[德国国家疾病管理指南“慢性心力衰竭”]
Dtsch Med Wochenschr. 2012 Feb;137(5):219-27. doi: 10.1055/s-0031-1292894. Epub 2012 Jan 25.
6
Characterization of the precipitants of hospitalization for heart failure decompensation.
Am J Crit Care. 1998 May;7(3):168-74.
7
Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.沙库巴曲缬沙坦、维立西呱和 SGLT2 抑制剂在射血分数降低的心力衰竭中的相对疗效：系统评价和网络荟萃分析。
Cardiovasc Drugs Ther. 2021 Oct;35(5):1067-1076. doi: 10.1007/s10557-020-07099-2. Epub 2020 Oct 19.
8
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective.从美国医疗保险角度看维立西呱治疗射血分数降低的慢性心力衰竭恶化后事件的成本效果
Pharmacoeconomics. 2021 Nov;39(11):1343-1354. doi: 10.1007/s40273-021-01091-w. Epub 2021 Oct 8.
9
Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.维立西呱对比安慰剂对射血分数保留的心力衰竭患者生活质量的影响：VITALITY-HFpEF 随机临床试验。
JAMA. 2020 Oct 20;324(15):1512-1521. doi: 10.1001/jama.2020.15922.
10
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e876-e894. doi: 10.1161/CIR.0000000000001062. Epub 2022 Apr 1.

引用本文的文献

1
Effects of Cardiac Rehabilitation Combined with Enhanced External Counterpulsation on Heart Rate Variability and Autonomic Nervous Function in Chronic Heart Failure.心脏康复联合增强型体外反搏对慢性心力衰竭患者心率变异性及自主神经功能的影响
Cardiovasc Toxicol. 2025 Aug 6. doi: 10.1007/s12012-025-10027-1.
2
The Complex Relationship Between Heart Failure and Chronic Obstructive Pulmonary Disease: A Comprehensive Review.心力衰竭与慢性阻塞性肺疾病之间的复杂关系：一项综述
J Clin Med. 2025 Jul 6;14(13):4774. doi: 10.3390/jcm14134774.
3
Native QRS duration and outcomes in heart failure with mildly reduced ejection fraction: results from a large-scaled registry.

本文引用的文献

1
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.铁羧基麦芽糖治疗急性心力衰竭出院后缺铁：一项多中心、双盲、随机、对照试验。
Lancet. 2020 Dec 12;396(10266):1895-1904. doi: 10.1016/S0140-6736(20)32339-4. Epub 2020 Nov 13.
2
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.肌球蛋白激活治疗收缩性心力衰竭的奥马曲珠单抗
N Engl J Med. 2021 Jan 14;384(2):105-116. doi: 10.1056/NEJMoa2025797. Epub 2020 Nov 13.
3
Efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure with volume overload: a prospective, randomized, controlled clinical trial.
射血分数轻度降低的心力衰竭患者的固有QRS波时限与预后：一项大型注册研究的结果
Clin Res Cardiol. 2025 May 12. doi: 10.1007/s00392-025-02667-8.
4
Impact of metoprolol combined with spironolactone on cardiac function in patients with coronary heart disease complicated by heart failure.美托洛尔联合螺内酯对冠心病合并心力衰竭患者心功能的影响
Am J Transl Res. 2025 Jan 15;17(1):664-673. doi: 10.62347/WWQN9188. eCollection 2025.
5
Differences in T cell-associated serum markers between ischemic cardiomyopathy and dilated cardiomyopathy.缺血性心肌病与扩张型心肌病之间T细胞相关血清标志物的差异。
J Thorac Dis. 2024 Jul 30;16(7):4655-4665. doi: 10.21037/jtd-24-901. Epub 2024 Jul 26.
早期超滤治疗容量超负荷的急性失代偿性心力衰竭患者的疗效和安全性：一项前瞻性、随机、对照临床试验。
BMC Cardiovasc Disord. 2020 Oct 14;20(1):447. doi: 10.1186/s12872-020-01733-5.
4
Artificial Intelligence-Enabled ECG Algorithm to Identify Patients With Left Ventricular Systolic Dysfunction Presenting to the Emergency Department With Dyspnea.基于人工智能的心电图算法识别因呼吸困难就诊于急诊科的左心室收缩功能障碍患者。
Circ Arrhythm Electrophysiol. 2020 Aug;13(8):e008437. doi: 10.1161/CIRCEP.120.008437. Epub 2020 Aug 4.
5
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
6
Factors associated with in-hospital mortality and adverse outcomes during the vulnerable post-discharge phase after the first episode of acute heart failure: results of the NOVICA-2 study.首发急性心力衰竭后易损出院期院内死亡率和不良结局的相关因素：NOVICA-2 研究结果。
Clin Res Cardiol. 2021 Jul;110(7):993-1005. doi: 10.1007/s00392-020-01710-0. Epub 2020 Sep 21.
7
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.钠-葡萄糖协同转运蛋白 2 抑制剂在射血分数降低的心力衰竭患者中的应用：EMPEROR-Reduced 和 DAPA-HF 试验的荟萃分析。
Lancet. 2020 Sep 19;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9. Epub 2020 Aug 30.
8
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
9
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).达格列净对心力衰竭预防试验（DAPA-HF）中基线收缩压的影响。
Eur Heart J. 2020 Sep 21;41(36):3402-3418. doi: 10.1093/eurheartj/ehaa496.
10
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.达格列净和利尿剂在 DAPA-HF 中射血分数降低的心力衰竭患者中的应用。
Circulation. 2020 Sep 15;142(11):1040-1054. doi: 10.1161/CIRCULATIONAHA.120.047077. Epub 2020 Jul 16.